BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 22, 2004
View Archived Issues
Critical Therapeutics Files For Estimated $103.5M IPO
Read More
Makeup Of Bush's Bioethics Committee Comes Under Fire
Read More
Chiron's Tezacitabine Scrapped After Phase II Trial Misses Goal
Read More
Other News To Note
Read More
$100M In Private Funds Expected To Expand Neurogen's Portfolio
Neurogen Corp.'s stock rose on Friday, following news that the company entered an agreement to privately sell $100 million worth of common shares. (BioWorld Today)
Read More